Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. The Company focuses on the developing and commercializing of in vitro diagnostic (IVD) tests for the screening and diagnosis of cancer. Epigenomics AG develops and markets cancer diagnostic tests in colorectal cancer (CRC) and in lung cancer. The Company’s main product is Epi proColon, a blood-based test for the early detection of CRC, which relies on its proprietary deoxyribonucleic acid (DNA) methylation biomarker, Septin9. Epi proColon is marketed in Europe and is in development for the United States. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. Epigenomics AG, as the parent company, oversees the Group’s central business functions, including accounting, human resources and intellectual property, among others.